Developing strategies for liver fibrosis treatment.
Liver fibrosis represents a major worldwide healthcare burden. Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of fibrosis. There is therefore a great need for novel therapies for liver fibrosis. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver fibrosis. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver fibrosis.
Murphy
Frank
F
Liver Research Group, Division of Infection, Inflammation & Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK. frm105@hotmail.com
Arthur
Michael
M
Iredale
John
J
D000818:Animals; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends